Name
*
First Name
Last Name
Email
*
example@example.com
Credentials
*
1. Which statement best captures the biologic rationale for targeting FXI/XIa in stroke prevention in AF rather than simply intensifying factor Xa inhibition?
*
A) To achieve more potent inhibition of the initiation phase of the coagulation cascade than Vitamin K Antagonists (VKAs).
B) To reduce thrombosis by targeting the amplification loop of the coagulation cascade while potentially preserving more physiologic hemostasis than current factor Xa-based DOAC therapy
C) To provide a faster-acting alternative to dual antiplatelet therapy (DAPT) for patients with acute myocardial infarction.
D) To eliminate the need for Thrombin (FIIa) generation during the consolidation phase of clot formation.
2. Which pairing correctly contrasts a zymogen-level monoclonal antibody strategy with an oral small-molecule FXIa inhibitor?
*
A. Monoclonal antibody: active-site inhibition with short half-life; small molecule: suppression of hepatic FXI synthesis
B. Monoclonal antibody: zymogen-level inhibition with prolonged effect; small molecule: active-site FXIa inhibition with oral dosing and shorter pharmacologic reversibility
C. Monoclonal antibody: factor Xa inhibition; small molecule: factor XI synthesis inhibition
D. Monoclonal antibody and small molecule: same mechanism, different branding
3. Which trial-population-control pairing is correct?
*
A. LIBREXIA-AF — AF unsuitable for anticoagulation — placebo
B. LILAC-TIMI 76 — guideline-eligible AF — apixaban
C. LIBREXIA-AF — AF/AFL indicated for OAC — apixaban
D. OCEANIC-AF — post-ablation AF — aspirin
4. Why does OCEANIC-AF remain important when interpreting ongoing Phase 3 FXI/XIa inhibitor programs in AF?
*
A. Because it showed that lower bleeding alone does not validate the FXI/XIa hypothesis in AF; adequate stroke/systemic embolism protection versus standard therapy must still be demonstrated
B. Because it proved that any level of FXI inhibition is automatically noninferior to apixaban for preventing stroke and systemic embolism in AF
C. Because it demonstrated that maximal suppression of free FXI activity in phase 2 guarantees both superior efficacy and less bleeding in subsequent phase 3 AF trials
D. Because it established that factor Xa inhibitors are no longer needed for stroke prevention in AF once FXI/XIa inhibitors become available
5. If a FXIa inhibitor were to demonstrate noninferior efficacy versus apixaban with less clinically relevant bleeding, which change would be most plausible first in electrophysiology practice?
*
A. Routine replacement of all DOACs in all AF patients
B. Selective use in preference-sensitive or high-bleeding-concern patients, including post-ablation and frail patients after shared decision-making
C. Elimination of the need for peri-procedural planning around ablation and cardioversion
D. Elimination of multidisciplinary coordination
6. In an EP clinic, which patient phenotype is most directly aligned with the clinical question being tested in LILAC-TIMI 76?
*
A. A standard-risk patient doing well on apixaban
B. A post-ablation patient asking whether all anticoagulation can stop after 3 months
C. A patient with AF who is considered unsuitable for current oral anticoagulation and is also not a practical LAAO candidate
D. A patient requiring dual antiplatelet therapy after STEMI
Submit
Should be Empty: